A Note from Cure Duchenne Founder, Debra Miller
January 11, 2010 by CureDuchenne
Filed under In The News
Today BioMarin announced they will initiate a human trial for a drug that will hopefully up-regulate Utrophin. This is very exciting news since we have hope that Utrophin could be an adequate substitute for dystrophin, the protein that is lacking in patients with Duchenne muscular dystrophy (DMD). This is the very first Utrophin drug to make it to human clinical trials – We applaud Dr. Kay Davies for developing this drug, to BioMarin for investing in this drug, and for Action Duchenne for helping fund it along the way.
My hope is that next year at this time, we will have several new drugs in the trial process for DMD and that the ones already in trial, prove to be effective and safe. The funding for the early development of these drugs is crucial and I’d like to encourage anyone who has an interest in curing DMD to become active in raising funds for research.
Of course, we’d love to have you join us in the many fundraising opportunities that CureDuchenne provides, such as our upcoming mountain climb and bike relay. These will be announced shortly.
Debra Miller
*
Related posts:
- BioMarin Initiates Phase 1 Clinical Study of BMN 195 for Duchenne Muscular Dystrophy Please take some time to read this important press release...
- Almost Half a Million Raised at Cure Duchenne Gala Cure Duchenne Founders, Paul and Debra Miller, were recently featured...
- Prosensa and GlaxoSmithKline Form Alliance to Fight Duchenne Muscular Dystrophy CureDuchenne is very pleased to forward this announcement from Prosensa. ...
- Mothers Luncheon Discusses Duchenne Muscular Dystrophy Yesterday, a group of 15 women from the LA/Orange County...
- Exciting Research Portfolio CureDuchenne’s mission is our name…to cure Duchenne muscular dystrophy. Our...
Related posts brought to you by Yet Another Related Posts Plugin.
